Regeneron Pharmaceuticals Inc, a developer of antibody therapeutics, is to acquire Decibel Therapeutics Inc, giving it ownership of three gene therapy programmes targeting different types of congenital, monogenic hearing loss. The two companies have been collaborating since 2017 and are now taking their lead therapy for congenital hearing loss forward to the clinic. The transaction, announced on 9 August, will involve a cash payment by Regeneron to Decibel of $4 per share for the target company’s common stock.
